尼妥珠单抗联合放疗治疗新诊断弥漫性内生性桥脑胶质瘤的III期临床研究
该III期研究纳入42例3至20岁临床及影像学确诊的DIPG患者,评估尼妥珠单抗(150 mg/m2每周静脉给药,共12周)联合同步外照射放疗(总剂量54 Gy,第3至9周)的疗效与安全性。主要终点为6个月无进展生存率,结果显示中位PFS为5.8个月,中位OS为9.4个月,客观缓解率为4.8%,门诊环境下该联合方案可行。
要点
- 42例DIPG患者接受尼妥珠单抗联合放疗,中位PFS 5.8个月,中位OS 9.4个月。
- 客观缓解率4.8%(2例部分缓解),疾病稳定27例(64.3%)。
- 最常见药物相关不良事件为脱发(14.3%),门诊治疗可行。
核心结论
- 尼妥珠单抗联合同步放疗在门诊环境下可行,其PFS和OS与住院环境下放疗联合强化化疗的结果相当。
研究设计与样本
- III期临床研究,纳入42例3至20岁临床和影像学确诊的DIPG患者,所有患者至少接受一剂尼妥珠单抗门诊治疗。
主要发现
- 42例中2例部分缓解(4.8%),27例疾病稳定(64.3%),10例疾病进展(23.8%),3例无法评估(7.1%)。
- 客观缓解率为4.8%,中位无进展生存期为5.8个月,中位总生存期为9.4个月。
- 最常见药物相关不良事件为脱发(14.3%),呕吐、头痛和放射性皮肤损伤各占7.1%。
- 治疗相关严重不良事件为瘤内出血和急性呼吸衰竭,难以与肿瘤进展效应区分。
关键数值与推荐
- 尼妥珠单抗静脉给药150 mg/m2,每周一次,共12周。
- 放疗总剂量54 Gy,于第3周至第9周照射。
- 第12周根据RECIST标准基于临床特征和MRI评估疗效。
- 此后患者每两周继续接受尼妥珠单抗直至疾病进展或不可管理的毒性。
- 不良事件依据CTC-AE版本3.0(CTC-AE3)评估。
临床怎么用
- 对于新诊断DIPG患者,可考虑尼妥珠单抗联合同步放疗的门诊治疗方案。
- 治疗期间需监测脱发、呕吐、头痛、放射性皮肤损伤等不良事件。
- 瘤内出血和急性呼吸衰竭需与肿瘤进展鉴别。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is a devastating cancer of childhood and adolescence. METHODS: The study included patients between 3 and 20 years with clinically and radiologically confirmed DIPG. Primary endpoint was 6-month progression-free survival (PFS) following administration of nimotuzumab in combination with external beam radiotherapy (RT). Nimotuzumab was administered intravenously at 150 mg/m2 weekly for 12 weeks. Radiotherapy at total dose of 54 Gy was delivered between week 3 and week 9. Response was evaluated based on clinical features and MRI findings according to RECIST criteria at week 12. Thereafter, patients continued to receive nimotuzumab every alternate week until disease progression/unmanageable toxicity. Adverse events (AE) were evaluated according to Common Terminology Criteria for Adverse Events (CTC-AE) Version 3.0 (CTC-AE3). RESULTS: All 42 patients received at least one dose of nimotuzumab in outpatient settings. Two patients had partial response (4.8%), 27 had stable disease (64.3%), 10 had progressive disease (23.8%) and 3 patients (7.1%) could not be evaluated. The objective response rate (ORR) was 4.8%. Median PFS was 5.8 months and median overall survival (OS) was 9.4 months. Most common drug-related AEs were alopecia (14.3%), vomiting, headache and radiation skin injury (7.1% each). Therapy-related serious adverse events (SAEs) were intra-tumoral bleeding and acute respiratory failure, which were difficult to distinguish from effects of tumor progression. CONCLUSIONS: Concomitant treatment with RT and nimotuzumab was feasible in an outpatient setting. The PFS and OS were comparable to results achieved with RT and intensive chemotherapy in hospitalized setting.
引用
- Fleischhack G, Massimino M, Warmuth-Metz M, et al. Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study. J Neurooncol. 2019. PMID: 30830679. doi:10.1007/s11060-019-03140-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。